Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients Receiving Trastuzumab, Pertuzumab, and Docetaxel or Paclitaxel With or Without Carboplatin: HALT-D

NCT02910219 is registered in ClinicalTrials.gov with Sandra Swain as lead sponsor.

NCT NCT02910219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02910219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients Receiving Trastuzumab, Pertuzumab, and Docetaxel or Paclitaxel With or Without Carboplatin: HALT-D
Lead sponsor
Sandra Swain
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2017
Completion date
November 23, 2020
Enrollment
53 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer